🔬 Silence APOC3, Slash Triglycerides, A New Era in Triglyceride Control

🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥   ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions   🔬 APOC3 inhibition emerges as a game-changer in lipidology. 📖 ESSENCE–TIMI 73b Trial | Funded by Ionis Pharmaceuticals   #Cardiology #LipidLowering #PrecisionMedicine #NEJM #Olezarsen #TGlowering #CVRisk #TIMI #Atherosclerosis #GenomicTherapy 🧬💊🫀